Y‐632 inhibits heat shock protein 90 (Hsp90) function by disrupting the interaction between Hsp90 and Hsp70/Hsp90 organizing protein, and exerts antitumor activity in vitro and in vivo

Heat shock protein 90 (Hsp90) stabilizes a variety of proteins required for cancer cell survival and has been identified as a promising drug target for cancer treatment. To date, several Hsp90 inhibitors have entered into clinical trials, but none has been approved for cancer therapy yet. Thus, expl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wenqian, Liu, Yang, Zhao, Zhixin, Xie, Chengying, Xu, Yongping, Hu, Youhong, Quan, Haitian, Lou, Liguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968598/
https://www.ncbi.nlm.nih.gov/pubmed/27002306
http://dx.doi.org/10.1111/cas.12934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968598/
https://www.ncbi.nlm.nih.gov/pubmed/27002306
http://dx.doi.org/10.1111/cas.12934

Ejemplares similares